NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

October 2011 Marketed Drug Updates and Additions

Brand Name

Generic Name

Other Designation

Nexavar

Sorafenib tosylate

BAY 43-9006

Sprycel

Dasatinib

BMS-354825

Yervoy

Ipilimumab

MDX-010, MDX-CTLA4; BMS-734016

Revlimid (formerly Revimid), Lenalidomide-Celgene Europe

Lenalidomide

CDC501, CDC-501, CDC-5013, CC5013, CC-5013

Valstar, Valtaxin (Canada)

Valrubicin

AD32

Herceptin

Trastuzumab

RG597, formerly rhuMAb HER2

Avastin

Bevacizumab

rhuMAb-VEGF, NSC-704865, R435, RG435

Velcade

Bortezomib

MLN341 (formerly LDP-341, PS-341 & MG-341)

Glutoxim (Russia)

 

BAM-002, NOV-002 (USA)

Photofrin (North America), Photobarr (Europe)

Porfimer sodium

 

Mepact (Europe), formerly Junovan (USA)

Mifamurtide

Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE), formerly CGP-19835A

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM